Boehringer Snaps Up T3 Amid Broader Immuno-Oncology Push

The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.

Boehringer Ingelheim said it would spend up to CHF450m to acquire T3 Pharma • Source: Shutterstock

Boehringer Ingelheim GmbH’s latest acquisition, of a private venture capital-backed immuno-oncology company in Switzerland, represents a new kind of therapeutic modality for the company, but still fits in with its long-term focus on oncology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By 

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.